Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Tissue Engineering, Biofabrication & 3D-Bioprinting in Life Sciences

Keith Murphy's Biography



Keith Murphy, CEO, Organovo

Mr. Murphy has more than 20 years of experience in biotechnology, including serving in Product Strategy and Director of Process Development roles at Amgen. He is a co-founder of Organovo and has been responsible for all company operations since 2007. His ten years at Amgen included four years as Global Operations Leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. At Amgen, he also worked to develop several other novel formulation and device products. Prior to Amgen, he played a central role at Alkermes, Inc. on the development team for their first approved product, Nutropin (hGH) Depot. He holds a B.S. in chemical engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management.

Keith Murphy Image

Bioprinting Industry Challenges and Solutions

Thursday, 17 March 2016 at 17:00

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

The field of bioprinting has the potential to impact the medical and life sciences fields in many ways in the coming decades.  Creating wins for patients that also benefit corporate stakeholders and employees takes a focus on many aspects of commercialization beyond winning technology.  Bioprinting scientists and executives need to understand and master key aspects of value creation, intellectual property, and negotiation with pharma and other technology end users to maximize the impact and overall success of the field.


Add to Calendar ▼2016-03-17 00:00:002016-03-18 00:00:00Europe/LondonTissue Engineering, Biofabrication and 3D-Bioprinting in Life SciencesTissue Engineering, Biofabrication and 3D-Bioprinting in Life Sciences in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com